Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.

6533b832fe1ef96bd129a56d

RESEARCH PRODUCT

Effects of PPARγ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells.

Marianna Terrasi Viviana Bazan Stefano Caruso Lavinia Insalaco Valeria Amodeo Daniele Fanale Lidia Rita Corsini C Contaldo A Mercanti E Fiorio Giuseppe Lo Re Giuseppe Cicero E Surmacz Antonio Russo Giuseppe Lo Re

subject

Leptin Vascular Endothelial Growth Factor A Physiology Settore MED/06 - Oncologia Medica Clinical Biochemistry Ligands chemistry.chemical_compound Cell Movement Promoter Regions Genetic skin and connective tissue diseases Receptor GENE-EXPRESSION Leptin digestive oral and skin physiology VEGF Gene Expression Regulation Neoplastic Vascular endothelial growth factor ROSIGLITAZONE ACTIVATED-RECEPTOR-GAMMA MCF-7 Cells PIOGLITAZONE Female medicine.medical_specialty Cell Survival Sp1 Transcription Factor BLADDER-CANCER Breast Neoplasms Biology Benzophenones Breast cancer Ciglitazone Internal medicine medicine Humans RNA Messenger Viability assay Binding Sites Leptin receptor Dose-Response Relationship Drug Cell Biology IN-VITRO medicine.disease TRANSACTIVATION DIABETIC-PATIENTS PPAR gamma Endocrinology chemistry Tyrosine THIAZOLIDINEDIONES ACTIVATED-RECEPTOR-GAMMA; BLADDER-CANCER; IN-VITRO; DIABETIC-PATIENTS; GENE-EXPRESSION; VEGF; PIOGLITAZONE; THIAZOLIDINEDIONES; TRANSACTIVATION; ROSIGLITAZONE Hormone

description

The obesity hormone leptin has been implicated in breast cancer development. Breast cancer cells express the leptin receptor and are able to synthesize leptin in response to obesity-related stimuli. Furthermore, leptin is a positive regulator of vascular endothelial growth factor (VEGF) and high levels of both proteins are associated with worse prognosis in breast cancer patients. Peroxisome proliferator-activated receptor γ (PPARγ) ligands are therapeutic agents used in patient with Type 2 diabetes and obesity which have recently been studied for their potential anti-tumor effect. Here, we studied if these compounds, ciglitazone and GW1929, can affect the expression of leptin and VEGF in breast cancer cells. In MDA-MB-231 and MCF-7 breast cancer cells, treatment with submolar concentrations of ciglitazone and GW1929 elevated the expression of leptin and VEGF mRNA and protein, and increased cell viability and migration. These effects coincided with increased recruitment of PPARγ to the proximal leptin promoter and decreased association of a transcriptional factor Sp1 with this DNA region.

year	journal	country	edition	language
2013-01-01

10.1002/jcp.24295 http://hdl.handle.net/10447/74733